Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Effective Corporate Tax Rate Down 5%, Max R&D Tax Break Rate Down to 20%
January 10, 2011
- CHMP Issues Positive Opinion for Taiho's TS-1
January 10, 2011
- Hope Is Not a Recruiting Strategy
January 10, 2011
- New Drugs Stimulate Osteoporosis Market: M3 Survey
January 10, 2011
- FDA Requests Additional Analytical Data for Ticagrelor
January 10, 2011
- Nippon Kayaku to Start Clinical Studies for Antibody Biosimilars in 2011
January 10, 2011
- MTPC Licenses Bepotastine to Dong-A of South Korea
January 10, 2011
- Small Pharmacy Operators to Create Their Own Association
January 10, 2011
- Taiyo Not to Reduce No. of Products It Manufactures
January 10, 2011
- Abbott Japan Starts Business Integration with Solvay
January 3, 2011
- Millennium, Seattle Genetics Report Favorable PII Results for Brentuximab in ALCL
January 3, 2011
- Novartis to Acquire Alcon
January 3, 2011
- Defendants Appeal Court Ruling on US Abilify Patent
January 3, 2011
- Hodanren, MIN-IREN Opposed to Premium for Development of New Drugs
January 3, 2011
- Nippon Kayaku Licenses Spanidin to Nordic Pharma Group
January 3, 2011
- NanoCarrier to Obtain Patents in Asia, Oceania
January 3, 2011
- MTPC, Novartis Apply for FTY720 in Japan
January 3, 2011
- Astellas Obtains Extended License on Seroquel ER Tab in Japan
January 3, 2011
- Mochida Ties Up with Gedeon Richter for Biosimilars
January 3, 2011
- Sanko Junyaku Acquires Marketing Rights for Flu Test Kit
January 3, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…